VBIO Overview

Valion Bio, Inc., formerly Tivic Health Systems, Inc., is a late-stage immunotherapeutics company. The Company offers Entolimod, which is a drug used to treat acute radiation syndrome (ARS). Entolimod is a toll-like receptor 5 (TLR5) agonist that activates an innate immune pathway to prevent cell death in the bone marrow and epithelial tissues across systems impacted by radiation and age. Its pipeline also includes Entolimod to treat neutropenia and lymphocyte exhaustion, as well as Entolasta, an immunologically optimized variant of Entolimod for chronic applications. Its subsidiary, Velocity Bioworks, is a full-service contract development and manufacturing organization (CDMO) that is based in San Antonio, Texas. It offers upstream and downstream process development and optimization; analytical testing, assay development, and qualification; quality control and stability testing; microbial and mammalian expression systems; technology transfer and program management services.

Wall Street analysts forecast VBIO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for VBIO is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Valion Bio Inc revenue for the last quarter amounts to 0.00 USD, decreased

Valion Bio Inc. EPS for the last quarter amounts to -1.65 USD, decreased -48.44

Valion Bio Inc (VBIO) has 52 emplpoyees as of May 10 2026.

Today VBIO has the market capitalization of 3.01M USD.